Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry.

O'Hearn A, Wang M, Cheng H, Lear-Rooney CM, Koning K, Rumschlag-Booms E, Varhegyi E, Olinger G, Rong L.

J Virol. 2015 May;89(10):5441-9. doi: 10.1128/JVI.03689-14. Epub 2015 Mar 4.

2.

Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.

Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L.

J Virol. 2015 Oct;89(19):9932-8. doi: 10.1128/JVI.01337-15. Epub 2015 Jul 22.

3.

Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus.

Kuroda M, Fujikura D, Nanbo A, Marzi A, Noyori O, Kajihara M, Maruyama J, Matsuno K, Miyamoto H, Yoshida R, Feldmann H, Takada A.

J Virol. 2015 Jun;89(12):6481-93. doi: 10.1128/JVI.03156-14. Epub 2015 Apr 8.

4.

Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β -/- interferon receptor-deficient mice.

Lever MS, Piercy TJ, Steward JA, Eastaugh L, Smither SJ, Taylor C, Salguero FJ, Phillpotts RJ.

J Med Microbiol. 2012 Jan;61(Pt 1):8-15. doi: 10.1099/jmm.0.036210-0. Epub 2011 Aug 18.

PMID:
21852521
5.

Filovirus entry: a novelty in the viral fusion world.

Hunt CL, Lennemann NJ, Maury W.

Viruses. 2012 Feb;4(2):258-75. doi: 10.3390/v4020258. Epub 2012 Feb 7. Review.

6.

Filoviruses utilize glycosaminoglycans for their attachment to target cells.

Salvador B, Sexton NR, Carrion R Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G.

J Virol. 2013 Mar;87(6):3295-304. doi: 10.1128/JVI.01621-12. Epub 2013 Jan 9.

7.

Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin.

Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, Kuhn JH, Sandwick S, Ruthel G, Kota K, Boltz D, Warren T, Kranzusch PJ, Whelan SP, Bavari S.

J Virol. 2010 Oct;84(20):10569-80. doi: 10.1128/JVI.00103-10. Epub 2010 Aug 4.

8.

Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.

Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W.

MBio. 2014 Jan 28;5(1):e00862-13. doi: 10.1128/mBio.00862-13.

9.

The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.

Brinkmann C, Nehlmeier I, Walendy-Gnirß K, Nehls J, González Hernández M, Hoffmann M, Qiu X, Takada A, Schindler M, Pöhlmann S.

J Virol. 2016 Nov 28;90(24):11075-11086. Print 2016 Dec 15.

10.

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ.

J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.

11.

Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.

Kuzmin IV, Schwarz TM, Ilinykh PA, Jordan I, Ksiazek TG, Sachidanandam R, Basler CF, Bukreyev A.

J Virol. 2017 Mar 29;91(8). pii: e02471-16. doi: 10.1128/JVI.02471-16. Print 2017 Apr 15.

12.

Characterization of Human and Murine T-Cell Immunoglobulin Mucin Domain 4 (TIM-4) IgV Domain Residues Critical for Ebola Virus Entry.

Rhein BA, Brouillette RB, Schaack GA, Chiorini JA, Maury W.

J Virol. 2016 Jun 10;90(13):6097-6111. doi: 10.1128/JVI.00100-16. Print 2016 Jul 1.

13.

Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.

Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, Bradfute SB, Gearhart JD, Retterer C, Kranzusch PJ, Misasi JN, Hogenbirk MA, Wahl-Jensen V, Volchkov VE, Cunningham JM, Jahrling PB, Aman MJ, Bavari S, Farzan M, Kuhn JH.

J Virol. 2011 Sep;85(17):8502-13. doi: 10.1128/JVI.02600-10. Epub 2011 Jun 22.

14.

Filoviruses: One of These Things is (not) Like the Other.

Anthony SM, Bradfute SB.

Viruses. 2015 Sep 29;7(10):5172-90. doi: 10.3390/v7102867. Review.

15.

Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.

Marzi A, Wegele A, Pöhlmann S.

Virology. 2006 Sep 1;352(2):345-56. Epub 2006 Jun 13.

16.

Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry.

Martin B, Hoenen T, Canard B, Decroly E.

Antiviral Res. 2016 Nov;135:1-14. doi: 10.1016/j.antiviral.2016.09.001. Epub 2016 Sep 14. Review.

PMID:
27640102
17.

Filovirus entry into cells - new insights.

Miller EH, Chandran K.

Curr Opin Virol. 2012 Apr;2(2):206-14. doi: 10.1016/j.coviro.2012.02.015. Epub 2012 Mar 23. Review.

18.

Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.

Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR.

Nature. 2011 Aug 24;477(7364):340-3. doi: 10.1038/nature10348.

19.

The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge.

Martinez O, Leung LW, Basler CF.

Antiviral Res. 2012 Mar;93(3):416-28. doi: 10.1016/j.antiviral.2012.01.011. Epub 2012 Feb 8. Review.

20.

Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.

Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M.

PLoS Pathog. 2011 Jan 6;7(1):e1001258. doi: 10.1371/journal.ppat.1001258.

Supplemental Content

Support Center